These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 28798092)
1. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Chee CBE; KhinMar KW; Sng LH; Jureen R; Cutter J; Lee VJM; Wang YT Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28798092 [No Abstract] [Full Text] [Related]
2. Shorter regimen for multi drug resistant tuberculosis cures more than 80% of patients. Cousins S BMJ; 2016 Oct; 355():i5807. PubMed ID: 27789468 [No Abstract] [Full Text] [Related]
3. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. van der Werf MJ; Hollo V; Ködmön C; Dara M; Catchpole M Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331041 [TBL] [Abstract][Full Text] [Related]
4. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Kendall EA; Fojo AT; Dowdy DW Lancet Respir Med; 2017 Mar; 5(3):191-199. PubMed ID: 27989591 [TBL] [Abstract][Full Text] [Related]
5. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Javaid A; Ahmad N; Khan AH; Shaheen Z Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049176 [No Abstract] [Full Text] [Related]
6. Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis. Sotgiu G; Tiberi S; D'Ambrosio L; Centis R; Alffenaar JW; Caminero JA; Abdo Arbex M; Alarcon Guizado V; Aleksa A; Dore S; Gaga M; Gualano G; Kunst H; Payen MC; Roby Arias AJ; Skrahina A; Solovic I; Sulis G; Tadolini M; Zumla A; Migliori GB; Eur Respir J; 2016 Nov; 48(5):1503-1507. PubMed ID: 27587544 [No Abstract] [Full Text] [Related]
7. Is Shorter Treatment Regimen for Multidrug-resistant Tuberculosis feasible in Indian Children? Shah I Indian Pediatr; 2017 Feb; 54(2):160. PubMed ID: 28285296 [No Abstract] [Full Text] [Related]
9. [Consideration on the use of injectable anti-tuberculosis drufgs in the treatment of drug-resistant tuberculosis in china]. Liu YH Zhonghua Jie He He Hu Xi Za Zhi; 2019 Jun; 42(6):401-404. PubMed ID: 31189224 [TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Balabanova Y; Fiebig L; Ignatyeva O; Riekstina V; Danilovits M; Jaama K; Davidaviciene E; Radiulyte B; Popa CM; Nikolayevskyy V; Drobniewski F Thorax; 2017 Sep; 72(9):850-852. PubMed ID: 28209653 [TBL] [Abstract][Full Text] [Related]
12. Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated. Yassin MA; Jaramillo E; Wandwalo E; Falzon D; Scardigli A; Kunii O; Weyer K Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331045 [No Abstract] [Full Text] [Related]
13. Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis. Seung KJ; Hewison C Lancet Glob Health; 2019 Jun; 7(6):e706. PubMed ID: 31005492 [No Abstract] [Full Text] [Related]
14. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. Van der Paardt AL; Akkerman OW; Gualano G; Palmieri F; Davies Forsman L; Aleksa A; Tiberi S; de Lange WC; Bolhuis MS; Skrahina A; van Soolingen D; Kosterink JG; Migliori GB; van der Werf TS; Alffenaar JC Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331034 [No Abstract] [Full Text] [Related]
15. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Catanzaro DG; Trollip AP; Seifert M; Georghiou SB; Garfein RS; Rodwell TC; Catanzaro A; Eisenach KD Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28381434 [TBL] [Abstract][Full Text] [Related]
17. Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India. Udwadia ZF; Ganatra S; Mullerpattan JB Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331036 [No Abstract] [Full Text] [Related]
18. Is it the time for abandoning longer regimens for drug-resistant tuberculosis. Singla R; Gupta A Indian J Tuberc; 2024; 71 Suppl 1():S3-S4. PubMed ID: 39067952 [No Abstract] [Full Text] [Related]
19. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. Lange C; Duarte R; Fréchet-Jachym M; Guenther G; Guglielmetti L; Olaru ID; Oliveira O; Rumetshofer R; Veziris N; van Leth F; Am J Respir Crit Care Med; 2016 Oct; 194(8):1029-1031. PubMed ID: 27685538 [No Abstract] [Full Text] [Related]
20. India should introduce daily drug treatment for tuberculosis. Jain Y BMJ; 2013 Nov; 347():f6769. PubMed ID: 24217439 [No Abstract] [Full Text] [Related] [Next] [New Search]